Please login to the form below

Not currently logged in
Email:
Password:

Minoyrx Therapeutics appoints chief medical officer

Dr Uwe Meya joins from Lupin Atlantis Holdings

Minoryx Therapeutics Dr Uwe MeyaSpanish orphan disease specialist Minoryx Therapeutics has appointed Dr Uwe Meya as its new chief medical officer.

Dr Meya brings over 30 years of research and development experience to the firm, with a background as a neurologist and psychiatrist.

He joins the Barcelona-based drug development company from Lupin Atlantis Holdings, where he oversaw its clinical strategy and implementation of studies in various therapeutic areas, including neurodegenerative disorders.

Prior to this, Dr Meya was head of phase I and II clinical studies in neurodegenerative disorders at Synosia Therapeutics, and served as head of research portfolio management and clinical research and licensing liaison manager in CNS at Roche.

He also has leadership experience working at Novartis in CNS clinical development, at Knoll as head of clinical development, and as a medical advisor and the head of clinical psychiatry at Schering.

Marc Martinell, chief executive officer of Minoryx Therapeutics, said: “We are delighted to welcome Dr Meya as our chief medical officer.

“Hi wealth of expertise in CNS-related research will help us significantly in moving forward the clinical development of our lead candidate MIN-102. He will also support the further development of our pipeline in orphan diseases.”

24th June 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....